Connection
Enrique Alvarez to Antibodies, Monoclonal
This is a "connection" page, showing publications Enrique Alvarez has written about Antibodies, Monoclonal.
|
|
Connection Strength |
|
![](https://profiles.ucdenver.edu/Framework/Images/connection_left.gif) |
|
![](https://profiles.ucdenver.edu/Framework/Images/connection_right.gif) |
|
0.389 |
|
|
|
-
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC. Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2022 08 25; 387(8):704-714.
Score: 0.131
-
Lovett-Racke AE, Yang Y, Liu Y, Gormley M, Kraus E, Graham C, Wray S, Racke MK, Alvarez E, Bass A, Fox E. B cell depletion changes the immune cell profile in multiple sclerosis patients: One-year report. J Neuroimmunol. 2021 10 15; 359:577676.
Score: 0.122
-
Lovett-Racke AE, Gormley M, Liu Y, Yang Y, Graham C, Wray S, Racke MK, Shubin R, Twyman C, Alvarez E, Bass A, Eubanks JL, Fox E. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. J Neuroimmunol. 2019 07 15; 332:187-197.
Score: 0.104
-
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, H?ring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 05; 28(6):910-924.
Score: 0.031
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|